Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02877615 | Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event | PHASE2 | COMPLETED | 585 | — | — | Dec 19, 2016 | Mar 10, 2019 | Mar 11, 2020 | 121 | Australia, Belgium +13 |
| Arm | Type | Description |
|---|---|---|
| S 44819 150 mg twice a day | EXPERIMENTAL | - |
| S 44819 300 mg twice a day | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| S 44819 150 mg twice a day | DRUG | One sachet of S 44819 150 mg and one sachet of placebo twice a day |
| S 44819 300 mg twice a day | DRUG | Two sachets of S 44819 150 mg twice a day |
| Placebo | DRUG | Two sachets of placebo twice a day |
Inclusion criteria : * Patients aged between 18 and 85 years (both inclusive) * Acute ischemic stroke that occured between 72 hours (3 days) and 192 hours (8 days) (both inclusive) before inclusion Exclusion criteria : * Any non-selection criteria, which could have occurred after the selection vi...